SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD
SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD — Progress Note 1 — Gwen Ifill — True-date frame: synthetic events are moved into the patient's historical lifetime. Codes, instruments, and treatments remain modern and are anachronistic.
| Patient | Gwen Ifill |
|---|
| Date of birth | 1955-09-29 |
|---|
| Identifiers | MRN HR-ML032-SYN-TD; SSN (made up) 000-32-5814 |
|---|
| Document date | 2016-01-05 |
|---|
| Author | Lorna Achebe-Price, MD |
|---|
| Custodian | St. Posthumous Health Center |
|---|
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Subjective
The patient attends this visit for three weeks of postmenopausal bleeding in a woman of 60: examination, office endometrial biopsy, transvaginal ultrasound, and gynecologic oncology review booked. [S]
Objective
Hemoglobin: 11.8 g/dL (low); White cell count: 6.2 10*3/uL; Platelets: 268 10*3/uL; Creatinine: 0.82 mg/dL; eGFR (CKD-EPI 2011): 82 mL/min/1.73 m²; Glucose: 94 mg/dL; Hemoglobin A1c: 5.5%; PHQ-2: 1. [S]
Vital Signs
| Date | Measure | Value | Unit | Provenance |
| 2016-01-05 | Body height | 165 | cm | S |
| 2016-01-05 | Body weight | 74.6 | kg | S |
| 2016-01-05 | Body mass index (BMI) [Ratio] | 27.4 | kg/m2 | S |
| 2016-01-05 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2016-01-05 | Diastolic blood pressure | 80 | mm[Hg] | S |
| 2016-01-05 | Heart rate | 78 | /min | S |
| 2016-01-05 | Respiratory rate | 16 | /min | S |
| 2016-01-05 | Body temperature | 36.7 | Cel | S |
| 2016-01-05 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
Results
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
| 2016-01-05 | Hemoglobin [Mass/volume] in Blood | 11.8 | g/dL | 12-15.5 g/dL | Low | S |
| 2016-01-05 | Leukocytes [#/volume] in Blood by Automated count | 6.2 | 10*3/uL | 4-11 10*3/uL | Normal | S |
| 2016-01-05 | Platelets [#/volume] in Blood by Automated count | 268 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2016-01-05 | Creatinine [Mass/volume] in Serum or Plasma | 0.82 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2016-01-05 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2011)/1.73 sq M | 82 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2016-01-05 | Glucose [Mass/volume] in Serum or Plasma | 94 | mg/dL | 70-99 mg/dL | Normal | S |
| 2016-01-05 | Hemoglobin A1c/Hemoglobin.total in Blood | 5.5 | % | Below 5.7% is normal; 5.7 to 6.4% prediabetes | Normal | S |
| 2016-01-05 | Patient Health Questionnaire 2 item (PHQ-2) total score [Reported] | 1 | {score} | | | S |
Allergies and Intolerances
| Allergy | Reaction | Status | Evidence |
|---|
| No known allergy | | active | S |
Problems
| Problem | Clinical status | Verification | Code | Provenance |
| Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked | active | confirmed |
N95.0 | S — Synthetic presenting problem; no symptom of her real illness was made public. Superseded by the diagnosis at the gynecologic oncology consultation. |
Assessment
- Postmenopausal bleeding for three weeks, about eight years after her last period, in a woman of 60 who takes no hormone therapy: endometrial cancer must be excluded. Office endometrial biopsy taken today, transvaginal ultrasound this week, and gynecologic oncology review booked: active, confirmed [S]
Plan of Treatment
- Gynecologic oncology consultation within two weeks to review the endometrial biopsy and ultrasound with her and plan treatment if cancer or atypical hyperplasia is found. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026) [S]
- Any bleeding after menopause is evaluated: speculum and bimanual examination, office endometrial biopsy at the first visit, and transvaginal ultrasound within the week, both done rather than relying on endometrial thickness alone; blood count and A1c; results by telephone within days, not at a routine visit. Guideline: Updated Guidance Regarding the Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Individuals With Postmenopausal Bleeding. Obstet Gynecol 2026;148(1):e87-e91 (PMID 41990335) (2026); Committee Opinion No. 734: The Role of Transvaginal Ultrasonography in Evaluating the Endometrium of Women With Postmenopausal Bleeding. Obstet Gynecol 2018;131(5):e124-e129 (PMID 29683909) (2018); Clarke MA, et al. Racial and Ethnic Differences in Hysterectomy-Corrected Uterine Corpus Cancer Mortality by Stage and Histologic Subtype. JAMA Oncol 2022;8(6):895-903 (PMID 35511145) (2022); Doll KM, et al. Assessment of Prediagnostic Experiences of Black Women With Endometrial Cancer in the United States. JAMA Netw Open 2020;3(5):e204954 (PMID 32412636) (2020) [S]
- Distress and depression screening at each visit, plain explanations, written information, and support she chooses; she decides who receives each note. Guideline: NCCN Clinical Practice Guidelines in Oncology: Uterine Neoplasms (2026); Depression and Suicide Risk in Adults: Screening (2023) [S]